{"createdAt":"8/2/2020, 2:33:22 PM","timestamp":1596393202468,"Company ID number":"609","DMX_ISSUER_NAME":"BEIJING TONGRENTANG CO., LTD","DMX_ISSUER_ID":"IID000000002141798","Country of Classification":"CHINA","name":"Beijing Tongrentang Co Ltd ","code":"600085","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"北京同仁堂股份有限公司_高振坤","group":"board","name":"高振坤","title":"董事长,董事","isMale":true,"age":"56","degree":"硕士","salary":"0.00","stockAmount":"-","description":"高振坤先生,研究生学历,高级会计师。曾任北京同仁堂药材有限责任公司党支部书记、总经理,北京同仁堂股份有限公司总会计师,北京同仁堂股份有限公司党委书记、副总经理,北京同仁堂股份有限公司董事、总经理,北京同仁堂投资发展有限责任公司董事,北京同仁堂商业投资集团有限公司董事长,北京同仁堂国药(中国香港)集团有限责任公司董事。现任中国北京同仁堂(集团)有限责任公司党委副书记、董事、总经理,北京同仁堂股份有限公司董事长,北京同仁堂科技发展股份有限公司董事长、执行董事、提名委员会主席及薪酬委员会委员。同时任北京市东城区第十六届人大代表,北京市第十五届人民代表大会代表。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_邸淑兵","group":"board","name":"邸淑兵","title":"董事","isMale":true,"age":"44","degree":"硕士","salary":"16.25万","stockAmount":"-","description":"邸淑兵先生,44岁,研究生学历,公共管理硕士,高级会计师。历任北京同仁堂药酒分公司财务主管,北京同仁堂药酒分公司副经理,北京同仁堂股份有限公司财务部副部长,北京同仁堂股份有限公司投资管理部副部长、部长,北京同仁堂商业投资集团党委委员、副总经理,中国北京同仁堂(集团)有限责任公司总经理助理兼经济运行部部长、北京同仁堂健康产业投资有限公司董事、北京同仁堂中药配方颗粒投资有限公司董事长、北京同仁堂生物制品开发有限公司董事、北京同仁堂化妆品有限公司董事。现任北京市企业联合会、北京市企业家协会副会长,北京同仁堂股份有限公司总经理。","lastUpdated":"2019-06-13"},{"id":"北京同仁堂股份有限公司_贾泽涛","group":"board","name":"贾泽涛","title":"董事","isMale":false,"age":"43","degree":"本科","salary":"50.97万","stockAmount":"-","description":"贾泽涛女士,大学学历,助理翻译。曾任北京同仁堂股份有限公司证券事务代表,中国北京同仁堂(集团)有限责任公司总经理助理、证券部部长。现任北京同仁堂股份有限公司董事会秘书。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_温凯婷","group":"board","name":"温凯婷","title":"董事","isMale":false,"age":"42","degree":"硕士","salary":"0.00","stockAmount":"-","description":"温凯婷女士,42岁,研究生学历,管理学硕士,中国注册会计师。曾任致同会计师事务所(普通合伙)高级经理,北京同仁堂股份有限公司副总会计师,北京同仁堂研究院副院长。现任同仁堂股份有限公司总会计师。","lastUpdated":"2020-06-20"},{"id":"北京同仁堂股份有限公司_臧怡","group":"board","name":"臧怡","title":"董事","isMale":false,"age":"43","degree":"本科","salary":"0.00","stockAmount":"-","description":"臧怡女士,大学学历,政工师。历任中国北京同仁堂(集团)有限责任公司组织部、人事干部部副部长,党委办公室主任、组织人事干部部副部长。现任中国北京同仁堂(集团)有限责任公司机关党总支书记、党委办公室主任、组织人事干部部副部长。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_刘柏钢","group":"board","name":"刘柏钢","title":"董事","isMale":true,"age":"52","degree":"本科","salary":"0.00","stockAmount":"-","description":"刘柏钢先生,大学学历,高级工程师。历任北京同仁堂制药厂质量保证部副科长、北京同仁堂股份有限公司科学研究所研发一部部长。现任中国北京同仁堂(集团)有限责任公司科技质量部副部长。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_满杰","group":"board","name":"满杰","title":"董事","isMale":false,"age":"46","degree":"本科","salary":"0.00","stockAmount":"-","description":"满杰女士,大学学历,中药师。历任北京同仁堂科技发展股份有限公司物价协调办公室副主任、物价协调办公室副主任兼财务党支部副书记。现任中国北京同仁堂(集团)有限责任公司物价招标办公室副主任。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_赵鹏","group":"board","name":"赵鹏","title":"董事","isMale":true,"age":"47","degree":"硕士","salary":"0.00","stockAmount":"-","description":"赵鹏,男,硕士研究生学历,经济师。曾先后担任中国人寿保险股份有限公司业务管理部高级主管,中国保险监督管理委员会发展改革部副处长、处长等职务。现任中国银行保险监督管理委员会派驻安邦保险集团接管工作组成员。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_吴星宇","group":"board","name":"吴星宇","title":"独立董事","isMale":true,"age":"44","degree":"硕士","salary":"10.00万","stockAmount":"-","description":"吴星宇先生,1976年出生,中国国籍,无境外永久居留权,硕士,持有中国注册会计师协会非执业会员证书、中国律师资格证书、美国特许金融分析师(CFA)证书。曾任职中国外汇交易中心职员,上海证券交易所执行经理,南京奥特佳新能源科技有限公司、奥特佳新能源科技股份有限公司副总经理兼财务总监,安徽铜峰电子股份有限公司、湖北济川药业股份有限公司独立董事。现任山鹰国际控股股份公司副总裁兼董事会秘书,上海普利特复合材料股份有限公司、北京同仁堂股份有限公司独立董事。2018年11月至今任国联证券股份有限公司独立董事。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_王瑛","group":"board","name":"王瑛","title":"独立董事","isMale":false,"age":"66","degree":"本科","salary":"10.00万","stockAmount":"-","description":"王瑛女士,大学学历,高级统计师。历任中国药材公司计划处副处长、处长,综合贸易部经理、药品部经理、中药事业部总经理、药品营销中心总经理、中药饮片事业部总经理。中国药材公司党委委员。现任中国中药协会执行副会长,北京同仁堂股份有限公司独立董事。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_王惠珍","group":"board","name":"王惠珍","title":"独立董事","isMale":false,"age":"66","degree":"本科","salary":"10.00万","stockAmount":"-","description":"王惠珍女士,大学学历,执业药师。历任北京大学第一医院药师、主管药师、副主任药师,药剂科行政副主任。现任北京同仁堂股份有限公司独立董事。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_刘渊","group":"board","name":"刘渊","title":"独立董事","isMale":true,"age":"73","degree":"本科","salary":"10.00万","stockAmount":"-","description":"刘渊先生,大学学历,经济师。历任北京市造纸包装工业公司办公室副主任、宣传部长、公司党委副书记,北京市第一轻工业总公司组织部长、党委副书记,北京市委工业工委副书记,北京一轻集团有限责任公司党委书记、副董事长,北京一轻控股有限责任公司党委书记、董事长。曾任北京汽车集团有限公司、中国北京同仁堂(集团)有限责任公司外部董事。现任北京同仁堂股份有限公司独立董事。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_毛福国","group":"supervisoryCommittee","name":"毛福国","title":"监事会主席","isMale":true,"age":"42","degree":"本科","salary":"0.00","stockAmount":"-","description":"毛福国先生,大学学历,中国注册会计师。曾任河北永正得会计师事务所审计项目助理、信永中和会计师事务所项目经理、致同会计师事务所(特殊普通合伙)高级审计经理,中国北京同仁堂(集团)有限责任公司财务运行部副部长。现任中国北京同仁堂(集团)有限责任公司财务运行部部长。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_闫军","group":"supervisoryCommittee","name":"闫军","title":"监事","isMale":true,"age":"55","degree":"本科","salary":"10.00万","stockAmount":"-","description":"闫军先生,大学学历,执业律师。1987年获北京大学法律系法学学士学位,同年8月起在北京市律师协会工作,1989年取得律师资格并在北京第五律师事务所执业,1994年组建北京市吴栾赵阎律师事务所并在该所执业至今,1996年取得律师从事证券法律业务资格。现为北京市吴栾赵阎律师事务所合伙人,北京同仁堂股份有限公司独立监事。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_王继雄","group":"supervisoryCommittee","name":"王继雄","title":"监事","isMale":true,"age":"35","degree":"本科","salary":"--","stockAmount":"-","description":"王继雄先生,35岁,大学学历,工学学士,政工师。曾任北京市纪委、北京市监委组织部主任科员,北京市纪委、北京市监委组织部二级主任科员,北京市纪委、北京市监委组织部一级主任科员。现任中国北京同仁堂(集团)有限责任公司党委巡察办公室(审计办公室)副主任。","lastUpdated":"2020-06-20"},{"id":"北京同仁堂股份有限公司_关庆维","group":"supervisoryCommittee","name":"关庆维","title":"职工监事","isMale":true,"age":"59","degree":"本科","salary":"28.00万","stockAmount":"-","description":"关庆维先生,大学学历,执业医师,主任医师。历任北京同仁堂股份有限公司同仁堂医馆副馆长,北京同仁堂股份有限公司同仁堂药店经理助理。现任中国北京同仁堂(集团)有限责任公司专家委员会专家,北京同仁堂药店副经理,同仁堂医馆馆长,世界中医联合会委员,中华医药学会会员,中国人体全息医疗学会会员,北京同仁堂中医药传承大师、同仁堂文化海外传承师、国家级非物质文化遗产项目代表性传承人名单中“同仁堂中医药文化”项目传承人,北京同仁堂股份有限公司监事。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_孙英","group":"supervisoryCommittee","name":"孙英","title":"职工监事","isMale":false,"age":"44","degree":"大专","salary":"42.43万","stockAmount":"-","description":"孙英女士,大专学历。曾就职于北京同仁堂股份有限公司财务部,历任北京同仁堂股份有限公司审计部主管、审计部副部长。现任北京同仁堂股份有限公司审计部部长。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_邸淑兵","group":"manager","name":"邸淑兵","title":"总经理","isMale":true,"age":"44","degree":"硕士","salary":"16.25万","stockAmount":"-","description":"邸淑兵先生,44岁,研究生学历,公共管理硕士,高级会计师。历任北京同仁堂药酒分公司财务主管,北京同仁堂药酒分公司副经理,北京同仁堂股份有限公司财务部副部长,北京同仁堂股份有限公司投资管理部副部长、部长,北京同仁堂商业投资集团党委委员、副总经理,中国北京同仁堂(集团)有限责任公司总经理助理兼经济运行部部长、北京同仁堂健康产业投资有限公司董事、北京同仁堂中药配方颗粒投资有限公司董事长、北京同仁堂生物制品开发有限公司董事、北京同仁堂化妆品有限公司董事。现任北京市企业联合会、北京市企业家协会副会长,北京同仁堂股份有限公司总经理。","lastUpdated":"2019-06-13"},{"id":"北京同仁堂股份有限公司_贾泽涛","group":"manager","name":"贾泽涛","title":"董事会秘书,副总经理","isMale":false,"age":"43","degree":"本科","salary":"50.97万","stockAmount":"-","description":"贾泽涛女士,大学学历,助理翻译。曾任北京同仁堂股份有限公司证券事务代表,中国北京同仁堂(集团)有限责任公司总经理助理、证券部部长。现任北京同仁堂股份有限公司董事会秘书。","lastUpdated":"2018-06-14"},{"id":"北京同仁堂股份有限公司_王田","group":"manager","name":"王田","title":"副总经理","isMale":true,"age":"51","degree":"本科","salary":"38.26万","stockAmount":"-","description":"王田先生,51岁,大学学历,执业药师,工程师。历任北京同仁堂制药厂质量科副科长,北京同仁堂股份有限公司制药厂生产科代理科长,北京同仁堂股份有限公司生产制造部副部长、部长,北京同仁堂股份有限公司制药厂北分厂副厂长、厂长、党总支书记(兼),北京同仁堂股份有限公司制药厂南分厂厂长,北京同仁堂股份有限公司总经理助理兼同仁堂制药厂大兴分厂厂长。现任北京同仁堂股份有限公司副总经理兼同仁堂制药厂大兴分厂厂长。","lastUpdated":"2019-03-26"},{"id":"北京同仁堂股份有限公司_张朝华","group":"manager","name":"张朝华","title":"副总经理","isMale":false,"age":"45","degree":"本科","salary":"9.310万","stockAmount":"-","description":"张朝华女士,45岁,大学学历,执业药师,高级工程师。历任北京同仁堂股份有限公司同仁堂制药厂南分厂一车间副主任、二车间技术副主任,北京同仁堂股份有限公司同仁堂制药厂亦庄分厂质量保证科副科长、综合办公室主任,中国北京同仁堂(集团)有限责任公司设备基建部副部长、工程管理部副部长、工装环保管理部副部长、科技质量部副部长,北京同仁堂制药有限公司董事。现任北京同仁堂股份有限公司副总经理。","lastUpdated":"2019-03-26"},{"id":"北京同仁堂股份有限公司_陈加富","group":"manager","name":"陈加富","title":"副总经理","isMale":true,"age":"51","degree":"硕士","salary":"9.310万","stockAmount":"-","description":"陈加富先生,51岁,研究生学历,主管药师,执业药师。历任北京同仁堂制剂厂生产科科长,北京同仁堂股份公司制药厂供应部副部长,北京同仁堂股份公司制药厂南分厂储运供应科科长,北京同仁堂股份公司制药厂南分厂厂长助理、副厂长,北京同仁堂股份公司制药厂亦庄分厂厂长,北京同仁堂科技发展股份有限公司党委副书记、纪委书记、工会主席,北京同仁堂科技发展股份有限公司党委委员、副总经理。现任北京同仁堂股份有限公司副总经理。","lastUpdated":"2019-04-30"},{"id":"北京同仁堂股份有限公司_温凯婷","group":"manager","name":"温凯婷","title":"总会计师","isMale":false,"age":"42","degree":"硕士","salary":"0.00","stockAmount":"-","description":"温凯婷女士,42岁,研究生学历,管理学硕士,中国注册会计师。曾任致同会计师事务所(普通合伙)高级经理,北京同仁堂股份有限公司副总会计师,北京同仁堂研究院副院长。现任同仁堂股份有限公司总会计师。","lastUpdated":"2020-06-20"}],"companyName":"北京同仁堂股份有限公司","province":"北京市","englishName":"Beijing Tongrentang Co., Ltd.","industry":"医药生物 — 中药Ⅱ","website":"gf.tongrentang.com","mainBusiness":"中药研发、生产、销售","productsName":["安宫牛黄丸","同仁牛黄清心丸","同仁大活络丸"],"actualController":"北京市国有资产监督管理委员会","actualControllerSharePercentage":"52.45%","registeredCapital":"13.71亿元","employeeAmount":"18398","phone":"86-010-67179780","location":"北京市东城区崇文门外大街42号","chineseDescription":"北京同仁堂股份有限公司的主营业务是中药研发、生产、销售；公司的主要产品是安宫牛黄丸、同仁牛黄清心丸、同仁大活络丸；同仁堂是中药行业久负盛名的中华老字号；同仁堂以安宫牛黄丸、同仁牛黄清心丸、同仁大活络丸为代表的十大王牌产品以及众多经典药品家喻户晓，蜚声海内外，在临床病患治疗中盛享美誉，公司业务覆盖 20 个国家及地区，零售终端达 71 个，形成了“立足中国香港，深耕主流，面向世界”的国际网络布局。公司使用的“同仁堂”商标属于控股股东同仁堂集团所有，该商标于一九八九年被国家工商行政管理局商标局认定为驰名商标。","foundedDate":"1997-06-18","goPublicDate":"1997-06-25","companyHistory":"北京同仁堂股份有限公司（以下简称本公司）系经北京市经济体制改革委员会京体改发（1997）11号批复批准，由中国北京同仁堂（集团）有限责任公司独家发起，以募集方式设立的股份有限公司。本公司于1997年5月29日发行人民币普通股5,000万股，1997年6月18日成立，注册资本200,000,000.00元，股本200,000,000股，并于1997年6月25日在上海证券交易所正式挂牌。本公司总部位于北京市崇文门外大街42号。\n　　根据本公司1998年度股东大会决议，本公司以1998年末总股本200,000,000股为基数，向全体股东按每10股送红股2股，共送红股40,000,000股。送股后股本总额为240,000,000股。\n　　根据本公司1999年度股东大会决议，本公司以1999年末总股本240,000,000股为基数，向全体股东按每10股配股3股，实际配股19,800,000股，其中：中国北京同仁堂（集团）有限责任公司实际配股1,800,000股，社会公众股实际配股18,000,000股，配股后股本总额为259,800,000股。\n　　根据本公司2000年度股东大会决议，本公司以2000年末总股本240,000,000股为基数，以资本公积向全体股东按每10股转增3股，即以配股后总股本259,800,000股为基数，每10股实际转增2.77136股，共转增71,999,933股。转增后股本总额为331,799,933股。\n　　根据本公司2002年度、2003年度股东大会决议，经中国证券监督管理委员会证监发行字[2004]141文核准，本公司以2002年末总股本331,799,933股为基数，向全体股东按每10股配股3股。本公司控股股东中国北京同仁堂（集团）有限责任公司全额放弃本次配股认购权，实际配股29,884,982股，配股后股本总额361,684,915股。\n　　根据本公司2004年度股东大会决议，本公司以2004年末总股本361,684,915股为基数，以资本公积向全体股东按每10股转增2股，共转增72,336,983股。转增后股本总额为434,021,898股。\n　　注册资本变更为434,021,898.00元。\n　　根据2005年11月22日相关股东大会审议通过的《北京同仁堂股份有限公司股权分置改革方案》，并经北京市人民政府国有资产监督管理委员会京国资产权字（2005）118号《关于北京同仁堂股份有限公司股权分置改革有关问题的批复》批复，本公司全体流通股股东每持有10股获得非流通股股东支付2.5股股票，流通股股东共获得非流通股股东38,850,477股股票，股本总额不变。\n　　根据本公司2007年度股东大会决议，本公司以2007年末总股本434,021,898股为基数，以资本公积向全体股东按每10股转增2股，共转增86,804,380股。转增后股本总额为520,826,278股。\n　　注册资本变更为520,826,278.00元。\n　　根据本公司2010年度股东大会决议，本公司以2010年末总股本520,826,278股为基数,每10股送红股5股，增加股本260,413,139股；以资本公积向全体股东按每10股转增10股，共转增520,826,278股，送转后，共增加股本781,239,417股，总股本为1,302,065,695股。注册资本变更为1,302,065,695.00元。\n　　根据本公司《发行可转换公司债券发行公告》，本公司可转换公司债券—同仁转债（转债代码：110022）于2013年6月5日起进入转股期。截至2015年3月3日，累计共有1,200,585,000元同仁转债已转换成本公司股票，转股数为69,404,567股，占同仁转债转股前公司已发行股份总额的5.33%。根据本公司第六届董事会第十八次会议关于提前赎回同仁转债的决议，本公司已行使同仁转债提前赎回权。2015年3月4日起，同仁转债和同仁转股（转股代码：190022）停止交易和转股。2015年3月10日，同仁转债在上海交易所摘牌。截至2015年12月31日，本公司总股本为1,371,470,262股。本公司于2015年7月8日完成工商变更登记手续，注册资本为1,371,470,262.00元。\n　　本公司建立了股东大会、董事会、监事会的法人治理结构，目前设药材采购部、生产制造部、品质保证部、人力资源部、销售部、进出口业务部、投资管理部、财务部、审计部等部门，拥有北京同仁堂科技发展股份有限公司（以下简称同仁堂科技）、北京同仁堂商业投资集团有限公司（以下简称同仁堂商业）、北京同仁堂天然药物有限公司（以下简称同仁堂天然药物）、北京同仁堂吉林人参有限责任公司（以下简称同仁堂吉林人参）、北京同仁堂陵川党参有限责任公司（以下简称同仁堂陵川党参）、北京同仁堂内蒙古甘草黄芪种植基地有限公司（以下简称同仁堂内蒙黄芪）、北京同仁堂蜂业有限公司（以下简称同仁堂蜂业）、北京同仁堂（安国）中药材加工有限责任公司、北京同仁堂股份集团（安国）中药材物流有限公司、北京同仁堂陕西麝业有限公司（以下简称同仁堂陕西麝业）等子公司。\n　　截至2019年12月31日，本公司总股本为1,371,470,262股。收起▲","shareholders":[{"organizationId":"00002767","holderName":"中国北京同仁堂(集团)有限责任公司","totalShare":"7.19亿","sharePercentage":"52.45%"},{"organizationId":"","holderName":"安邦人寿保险股份有限公司-保守型投资组合","totalShare":"1.26亿","sharePercentage":"9.19%"},{"organizationId":"","holderName":"安邦人寿保险股份有限公司-积极型投资组合","totalShare":"7958.97万","sharePercentage":"5.80%"},{"organizationId":"T000073058","holderName":"中国证券金融股份有限公司","totalShare":"4103.38万","sharePercentage":"2.99%"},{"organizationId":"","holderName":"全国社保基金一零三组合","totalShare":"3988.82万","sharePercentage":"2.91%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"1824.07万","sharePercentage":"1.33%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"1230.94万","sharePercentage":"0.90%"},{"organizationId":"","holderName":"安本标准投资管理(亚洲)有限公司-安本标准-中国A股股票基金","totalShare":"687.52万","sharePercentage":"0.50%"},{"organizationId":"","holderName":"农银人寿保险股份有限公司-分红保险产品","totalShare":"661.10万","sharePercentage":"0.48%"},{"organizationId":"","holderName":"农银人寿保险股份有限公司-传统保险产品","totalShare":"532.26万","sharePercentage":"0.39%"}],"englishDescription":"BEIJING TONGRENTANG CO., LTD is a China-based company principally engaged in the production and sales of traditional Chinese patent medicines. The Company鈥檚 main products consist of liuwei dihuang series, tongren dahuoluo series, tongren niuhuang qingxin series, angong niuhuang series and donkey-hide gelatin series. The Company distributes its products under the brand of Tongrentang. The Company is also involved in the operation of Tongrentang drug stores. The Company distributes its products in domestic market and to overseas markets.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"42.37","Price to sales (ttm)":"2.99","Price to book (mrq)":"3.91","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"18.76","Lt debt to equity (mrq)":"12.89","Return on investment (ttm)":"12.55","Return on equity (ttm)":"6.39","Income statement":{},"Balance sheet":{},"Cash flow":{"Cash receipts":"14,280.47","Cash payments":"(6,143.53)","Cash taxes paid":"(1,249.45)","Changes in working capital":"(4,613.78)","Cash from operating activities":"2,273.71","Capital expenditures":"(463.81)","Other investing cash flow items, total":"146.46","Cash from investing activities":"(317.35)","Financing cash flow items":"(445.47)","Total cash dividends paid":"(1,081.17)","Issuance (retirement) of debt, net":"232.65","Cash from financing activities":"(1,293.99)","Foreign exchange effects":"40.52","Net change in cash":"702.89"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"27.04","52 Week High":"30.25","52 Week Low":"23.99","Pricing date":"","10 Day Average Trading Volume":"10.43","Market Capitalization":"37,084.55","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"179.08","Beta":"1.21","1 Day Price Change":"-0.66","13 Week Price Return (Daily)":"5.30","26 Week Price Return (Daily)":"-1.13","5 Day Price Return (Daily)":"2.66","52 Week Price Return (Daily)":"-3.57","Year To Date Price Return (Daily)":"-4.05","Month to Date Price Return (Daily)":"-0.29","Price Relative to S&P500 (4 Week)":"-7.95","Price Relative to S&P500 (13 Week)":"-9.02","Price Relative to S&P500 (26 Week)":"-11.09","Price Relative to S&P500 (52 Week)":"-15.26","Price Relative to S&P500 (YTD)":"-11.58"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.72","EPS excl. Extra Items (TTM)":"0.64","EPS Normalized (Annual)":"0.69","Revenue per Share (Annual)":"9.68","Revenue per Share (TTM)":"9.04","Book Value (Per Share Annual)":"6.73","Book Value (Per Share Quarterly)":"6.92","Tangible Book Value (Per Share Annual)":"6.38","Tangible Book Value (Per Share Quarterly)":"6.57","Cash Per Share (Per Share Annual)":"5.54","Cash Per Share (Per Share Quarterly)":"5.90","Cash Flow (Per Share Annual)":"1.32","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.76","Dividends (Per Share TTM)":"0.76","EBITD (Per Share TTM)":"1.21","EPS Basic excl. Extra Items (Annual)":"0.72","EPS Basic excl. Extra Items (TTM)":"0.64","EPS incl. Extra Items (Annual)":"0.72","EPS incl. Extra Items (TTM)":"0.64","Free Cash Flow (Per Share TTM)":"0.52","Dividend (Per Share 5Y)":"0.35"},"Valuation":{"P/E excl. Extra Items (Annual)":"37.63","P/E excl. Extra Items (TTM)":"42.37","P/E Normalized (Annual)":"39.06","Price to sales (Annual)":"2.79","Price to sales (TTM)":"2.99","Price to Tangible Book (Annual)":"4.24","Price to Tangible Book (Quarterly)":"4.11","Price to Free Cash Flow (Per Share Annual)":"50.89","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"51.62","Price to Book (Annual)":"4.02","Price to Book (Quarterly)":"3.91","P/E Basic excl. Extra Items (TTM)":"39.72","P/E excl. Extra Items High (TTM)":"69.89","P/E excl. Extra Items Low (TTM)":"32.51","P/E incl. Extra Items (TTM)":"42.37","Net Debt (Interim)":"-6,310.10","Net Debt (Annual)":"-5,339.06","Dividend Yield (5Y)":"1.06","Dividend Yield":"2.81","Current Dividend Yield (TTM)":"2.81"},"Financial Strength":{"Free Cash Flow (Annual)":"728.73","Current Ratio (Annual)":"3.29","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"13.32","Payout Ratio (Annual)":"36.19","Quick Ratio (Annual)":"2.08","Total Debt/Total Equity (Annual)":"24.40","Current EV/Free Cash Flow (Annual)":"140.10","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"3.38","Long Term Debt/Equity (Quarterly)":"12.89","Quick Ratio (Quarterly)":"2.17","Total Debt/Total Equity (Quarterly)":"18.76","Free Cash Flow (TTM)":"718.37","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"40.74"},"Margins":{"Gross Margin (Annual)":"45.75","Gross Margin (TTM)":"46.36","Net Profit Margin % (Annual)":"11.76","Net Profit Margin (TTM)":"10.90","Operating Margin (Annual)":"14.79","Operating Margin (TTM)":"13.99","Pretax Margin (TTM)":"13.89","Pretax Margin (Annual)":"14.81","Operating Margin (5Y)":"15.70","Pretax Margin (5Y)":"15.75","Free Operating Cash Flow/Revenue (5Y)":"2.94","Free Operating Cash Flow/Revenue (TTM)":"5.80","Gross Margin (5Y)":"45.69","Net Profit Margin (5Y)":"12.77"},"Management Effectiveness":{"Return on Assets (Annual)":"7.54","Return on Equity (TTM)":"6.39","Return on Average Equity (Annual)":"10.66","Return on Average equity (TTM)":"9.18","Return on Investment (Annual)":"14.90","Return on Investment (TTM)":"12.55","Return on Average Assets (5Y)":"9.31","Return on Average Equity (5Y)":"12.37","Return on Investment (5Y)":"18.28","Asset Turnover (Annual)":"0.64","Asset Turnover (TTM)":"0.59","Inventory Turnover (Annual)":"1.18","Inventory Turnover (TTM)":"1.12","Net Income/Employee (Annual)":"87,885.94","Net Income/Employee (TTM)":"73,461.77","Receivables Turnover (Annual)":"11.05","Receivables Turnover (TTM)":"8.06","Revenue/Employee (Annual)":"747,228.10","Revenue/Employee (TTM)":"673,773.80"},"Growth":{"Revenue Growth (Quarterly YoY)":"-22.53","Revenue Growth Rate (5Y)":"6.51","EPS Growth (Quarterly YoY)":"-31.55","EPS Growth (TTM YoY)":"-24.97","EPS Growth Rate (5Y)":"4.29","Dividend Growth Rate (3Y)":"46.85","Revenue Growth (TTM YoY)":"-14.25","Revenue Growth (Per Share 5Y)":"5.56","Revenue Growth Rate (3Y)":"3.17","EPS Growth Rate (3Y)":"1.83","Book Value Growth Rate (Per Share 5Y)":"9.85","Tangible Book Value Total Equity CAGR (5Y)":"10.99","Capital Spending growth rate 5 year":"-3.73","EBITDA CAGR (5Y)":"5.76","EBITDA Interim CAGR (5Y)":"1.50","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"14.18","Net Profit Margin Growth Rate (5Y)":"-1.90"},"Income Statement":{"Revenue (Annual)":"13,277.12","Revenue (TTM)":"12,396.09","EBITD (Annual)":"2,116.96","EBITD (TTM)":"1,657.19","Earnings Before Taxes (Annual)":"1,966.69","Earnings Before Taxes (TTM)":"1,721.55","Net Income to Common (Annual)":"985.44","Net Income to Common (TTM)":"875.30","Earnings Before Taxes Normalized (Annual)":"1,921.26","Net Income Available to Common Normalized (Annual)":"949.36","Diluted Normalized EPS excl. Extra Items (TTM)":"0.61"}}}